Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters











Database
Publication year range
1.
Ann Hematol ; 99(4): 877-884, 2020 Apr.
Article in English | MEDLINE | ID: mdl-32062742

ABSTRACT

Autologous stem cell transplant (ASCT) is a widely used and safe procedure to treat mostly hematologic diseases. These patients are at risk of infectious complications, which represents a major cause of morbidity and it is the second cause of mortality. This retrospective 12-year analysis of the incidence, type, and severity of infections in 266 consecutive unselected ASCT patients at our institution provides novel information addressing this issue. We included 266 ASCT procedures. Patients included in the 2006-2013 period are referred to as group 1 (ciprofloxacin prophylaxis and ceftazidime-amikacin as empirical antibiotics), and those in the 2013-2017 period are group 2 (levofloxacin prophylaxis and meropenem as empirical antibiotics). The incidence of febrile neutropenia was 72% in group 1 and 86.2% in group 2 (p = 0.004). The majority of infectious episodes were associated with fever of unknown origin: 55% in group 1 and 59% in group 2. Febrile of unknown origin episodes were 82.6% in group 1 and 80% in group 2. Significant differences between both groups were found in age, hypogammaglobulinemia, and advanced disease at ASCT. No differences were found between groups regarding the most common agent documented in positive blood cultures (Gram+ were 66.6% in group 1 and 69% in group 2 (p = 0.68)). Mortality within 100 days of transplant was low, 1.87%. Regardless of the prophylactic regimen used, most patients experience febrile episodes in the ASCT setting, fever of unknown origin is the most common infection complication, and Gram+ agents are prevalent in both groups. Mortality rates were low. According to our results, ASCT is a safe procedure and there is no clear benefit in favor of levofloxacin versus ciprofloxacin prophylaxis. Both anti-infectious approaches are acceptable, yielding similar outcomes.


Subject(s)
Antibiotic Prophylaxis , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Bacteremia/prevention & control , Febrile Neutropenia/prevention & control , Adolescent , Adult , Aged , Amikacin/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Bacteremia/etiology , Ceftazidime/therapeutic use , Ciprofloxacin/therapeutic use , Febrile Neutropenia/chemically induced , Female , Fever of Unknown Origin/prevention & control , Hematologic Neoplasms/drug therapy , Hematologic Neoplasms/therapy , Humans , Incidence , Levofloxacin/therapeutic use , Male , Meropenem/therapeutic use , Middle Aged , Peripheral Blood Stem Cell Transplantation/methods , Retrospective Studies , Transplantation, Autologous , Uruguay , Young Adult
2.
Internist (Berl) ; 55(8): 976-80, 2014 Aug.
Article in German | MEDLINE | ID: mdl-24831684

ABSTRACT

A 55-year-old woman presented 18 months after a trip to Ecuador with night sweat, malaise, and an unclear lesion of the lung. Computed tomography of the lung showed a nodular lesion of 14 mm. Antibodies against Histoplasma capsulatum were detected in the complement fixation text (CFT) and IgG western blot. Re-examination of a formalin fixed paraffin embedded (FFPE) lung-biopsy revealed yeasts after silver staining, compatible with H. capsulatum , which was verified by extraction and amplification of DNA from FFPE. After therapy with itraconazole 400 mg/day, the patient showed an uneventful clinical recovery without regression of the lung lesion. The serological follow-up examination after 17 months showed CFT without pathological findings.


Subject(s)
Arthritis/prevention & control , Exanthema/prevention & control , Fever of Unknown Origin/prevention & control , Histoplasmosis/diagnosis , Histoplasmosis/drug therapy , Travel , Antifungal Agents/therapeutic use , Arthritis/diagnosis , Arthritis/immunology , Complement Fixation Tests , Cough/diagnosis , Cough/immunology , Cough/prevention & control , Ecuador , Exanthema/diagnosis , Exanthema/immunology , Female , Fever of Unknown Origin/diagnosis , Fever of Unknown Origin/immunology , Histoplasmosis/immunology , Humans , Itraconazole/therapeutic use , Middle Aged
3.
Am J Infect Control ; 41(4): 357-9, 2013 Apr.
Article in English | MEDLINE | ID: mdl-23102987

ABSTRACT

In a quasiexperimental study conducted to evaluate the impact of a Protective Environment implementation, febrile neutropenia (P = .009), overall mortality (P = .001), and 30-day adjusted mortality (P = .02) were reduced in cancer patients with chemotherapy-induced neutropenia. Our study highlights the potential success of a set of prevention measures mainly designed to reduce invasive environmental fungal infections in allogeneic hematopoietic stem cell transplant patients, in reducing fever and mortality among neutropenic cancer patients.


Subject(s)
Air Pollution, Indoor , Drug Therapy/methods , Drug-Related Side Effects and Adverse Reactions , Fever of Unknown Origin/mortality , Fever of Unknown Origin/prevention & control , Hematologic Neoplasms/drug therapy , Neutropenia/chemically induced , Adult , Aged , Female , Humans , Incidence , Male , Middle Aged , Survival Analysis
SELECTION OF CITATIONS
SEARCH DETAIL